as 03-31-2025 2:39pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 592.7M | IPO Year: | N/A |
Target Price: | $25.50 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.02 | EPS Growth: | N/A |
52 Week Low/High: | $6.79 - $23.48 | Next Earning Date: | 05-01-2025 |
Revenue: | $53,883,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 13.15% | Revenue Growth (next year): | 221.86% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Bair Teresa Brophy | KURA | Chief Legal Officer | Jan 28 '25 | Sell | $7.87 | 7,281 | $57,315.30 | 112,792 | |
DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 28 '25 | Sell | $7.87 | 4,949 | $38,958.03 | 90,014 | |
FORD KATHLEEN | KURA | Chief Operating Officer | Jan 28 '25 | Sell | $7.87 | 1,817 | $14,303.24 | 21,367 | |
Powl Brian T. | KURA | Chief Commercial Officer | Jan 28 '25 | Sell | $7.87 | 1,583 | $12,461.22 | 59,667 | |
Leoni Mollie | KURA | Chief Medical Officer | Jan 28 '25 | Sell | $7.87 | 4,963 | $39,068.24 | 88,253 | |
Burrows Francis | KURA | Chief Scientific Officer | Jan 28 '25 | Sell | $7.87 | 2,166 | $17,050.54 | 20,705 |
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
GlobeNewswire
24 days ago
MT Newswires
25 days ago
Simply Wall St.
a month ago
Thomson Reuters StreetEvents
a month ago
GuruFocus.com
a month ago
Zacks
a month ago
Associated Press Finance
a month ago
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.